Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GPCR |
---|---|---|
09:32 ET | 8621 | 48.3 |
09:34 ET | 500 | 48.02 |
09:36 ET | 615 | 47.99 |
09:38 ET | 1350 | 47.995 |
09:39 ET | 4662 | 48.799 |
09:41 ET | 57389 | 48.5826 |
09:43 ET | 8425 | 48.585 |
09:45 ET | 4000 | 49.1243 |
09:48 ET | 2050 | 49.68 |
09:50 ET | 10255 | 49.42 |
09:52 ET | 3100 | 49.3728 |
09:54 ET | 5451 | 49.015 |
09:56 ET | 5540 | 49.17 |
09:57 ET | 205 | 49.0463 |
09:59 ET | 2695 | 49.0208 |
10:01 ET | 2903 | 48.76 |
10:03 ET | 1911 | 48.8727 |
10:06 ET | 3300 | 48.28 |
10:08 ET | 400 | 48.2 |
10:10 ET | 4105 | 48.2 |
10:12 ET | 2662 | 48.15 |
10:14 ET | 500 | 48 |
10:15 ET | 400 | 48.01 |
10:17 ET | 1200 | 47.9999 |
10:19 ET | 4336 | 47.705 |
10:21 ET | 2380 | 47.9921 |
10:24 ET | 110 | 47.7001 |
10:26 ET | 100 | 47.815 |
10:28 ET | 450 | 47.79 |
10:30 ET | 3500 | 47.88 |
10:32 ET | 6280 | 48.04 |
10:33 ET | 100 | 48.15 |
10:35 ET | 3176 | 47.825 |
10:37 ET | 1750 | 47.86 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Structure Therapeutics Inc | 2.7B | -20.6x | --- |
Xenon Pharmaceuticals Inc | 2.8B | -13.8x | --- |
MoonLake Immunotherapeutics | 2.6B | -54.6x | --- |
Geron Corp | 2.9B | -13.6x | --- |
SpringWorks Therapeutics Inc | 2.9B | -7.4x | --- |
Biohaven Ltd | 3.0B | -4.9x | --- |
Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases. It is focused on G-protein coupled receptors (GPCRs) as a therapeutic target class. Its product candidates include GSBR-1290, Amylin, glucose-dependent insulinotropic polypeptide receptor (GIPR), GCGR, ANPA-0073 and LTSE-2578. It is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor (GLP-1R) for the treatment of type 2 diabetes mellitus (T2DM) and obesity. It is developing GLP-1R candidates, including dual GLP-1R/GIPR agonists and amylin agonists, each designed with customized properties to achieve additional benefit. It is developing ANPA-0073, an investigational oral small molecule APJR agonist, for the treatment of idiopathic pulmonary fibrosis (IPF). It is evaluating its LPA1R program, LTSE-2578 for IPF and progressive pulmonary fibrosis.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 57.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.32 |
Book Value | $9.76 |
P/E Ratio | -20.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.